Eight Reasons BioViva Will Dominate the Gene Therapy Industry

<p>Indispensability creates industry leaders.&nbsp;<strong>BioViva&rsquo;s&nbsp;</strong>CMV gene delivery system does what other vectors cannot.</p> <p>Current vectors provide scanty palettes and frayed brushes to prospective gene therapists, keeping the lion&rsquo;s share of use cases outside their reach.</p> <p>Gene therapy&rsquo;s full potential can only be unleashed through large and redosable vectors like&nbsp;<strong>BioViva&rsquo;s&nbsp;</strong>CMV.</p> <p>It will be impossible to tackle complex diseases without large vectors. These are the most common and costly health issues in the developed world: Alzheimer&rsquo;s, cancer, renal diseases, COPD, heart disease, diabetes, Parkinson&rsquo;s, and, of course, aging itself.</p> <p><a href="https://bioviva-science.medium.com/eight-reasons-bioviva-will-dominate-the-gene-therapy-industry-191c8ebef94c"><strong>Website</strong></a></p>